Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.
Article
PubMed
Google Scholar
Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med. 2005, 352: 476-487. 10.1056/NEJMra040958.
Article
CAS
PubMed
Google Scholar
Fletcher RH: The diagnosis of colorectal cancer in patients with symptoms: finding a needle in a haystack. BMC Med. 2009, 7: 18-10.1186/1741-7015-7-18.
Article
PubMed
PubMed Central
Google Scholar
Bathe OF, Ernst S, Sutherland FR, Dixon E, Butts C, Bigam D, Holland D, Porter GA, Koppel J, Dowden S: A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer. 2009, 9: 156-10.1186/1471-2407-9-156.
Article
PubMed
PubMed Central
Google Scholar
Balko JM, Black EP: A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer. 2009, 9: 145-10.1186/1471-2407-9-145.
Article
PubMed
PubMed Central
Google Scholar
Ohtani H: Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun. 2007, 7: 4-
PubMed
PubMed Central
Google Scholar
Atreya I, Neurath MF: Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther. 2008, 8: 561-572. 10.1586/14737140.8.4.561.
Article
CAS
PubMed
Google Scholar
Pagès F, Galon J, Fridman WH: The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol. 2008, 84: 981-987. 10.1189/jlb.1107773.
Article
PubMed
Google Scholar
Galon J, Fridman WH, Pagès F: The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007, 67: 1883-1886. 10.1158/0008-5472.CAN-06-4806.
Article
CAS
PubMed
Google Scholar
Camus M, Tosolini M, Mlecnik B, Pagès F, Kirilovsky A, Berger A, Costes A, Bindea G, Charoentong P, Bruneval P, Trajanoski Z, Fridman WH, Galon J: Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 2009, 69: 2685-2693. 10.1158/0008-5472.CAN-08-2654.
Article
CAS
PubMed
Google Scholar
Zlobec I, Terracciano LM, Lugli A: Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes. Clin Cancer Res. 2008, 14: 3792-3797. 10.1158/1078-0432.CCR-08-0048.
Article
CAS
PubMed
Google Scholar
Wagner P, Koch M, Nummer D, Palm S, Galindo L, Autenrieth D, Rahbari N, Schmitz-Winnenthal FH, Schirrmacher V, Büchler MW, Beckhove P, Weitz J: Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann Surg Oncol. 2008, 15: 2310-2317. 10.1245/s10434-008-9971-5.
Article
PubMed
Google Scholar
Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C: Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med. 2007, 5: 62-10.1186/1479-5876-5-62.
Article
PubMed
PubMed Central
Google Scholar
Halama N, Michel S, Kloor M, Zoernig I, Pommerencke T, von Knebel Doeberitz M, Schirmacher P, Weitz J, Grabe N, Jäger D: The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun. 2009, 9: 1-
PubMed
PubMed Central
Google Scholar
Morris M, Platell C, Iacopetta B: Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res. 2008, 14: 1413-1417. 10.1158/1078-0432.CCR-07-1994.
Article
CAS
PubMed
Google Scholar
Pagès F, Berger A, Camus M, Sanch ez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005, 353: 2654-2666. 10.1056/NEJMoa051424.
Article
PubMed
Google Scholar
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313: 1960-1964. 10.1126/science.1129139.
Article
CAS
PubMed
Google Scholar
Masopust D, Vezys V, Marzo AL, Lefrançois L: Preferential localization of effector memory cells in nonlymphoid tissue. Science. 2001, 291: 2413-2417. 10.1126/science.1058867.
Article
CAS
PubMed
Google Scholar
Vezys V, Yates A, Casey KA, Lanier G, Ahmed R, Antia R, Masopust D: Memory CD8 T-cell compartment grows in size with immunological experience. Nature. 2009, 457: 196-199. 10.1038/nature07486.
Article
CAS
PubMed
Google Scholar
Clémenceau B, Vivien R, Berthomé M, Robillard N, Garand R, Gallot G, Vollant S, Vié H: Effector memory alphabeta T lymphocytes can express FcgammaRIIIa and mediate antibody-dependent cellular cytotoxicity. J Immunol. 2008, 180: 5327-5334.
Article
PubMed
Google Scholar
Woodland DL, Kohlmeier JE: Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol. 2009, 9: 153-161. 10.1038/nri2496.
Article
CAS
PubMed
Google Scholar
Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G: Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol. 2005, 23: 8950-8958. 10.1200/JCO.2005.12.147.
Article
CAS
PubMed
Google Scholar
Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, Rotundo MS, Ginanneschi C, Martellucci I, Francini E, Cusi MG, Tassone P, Francini G: Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res. 2008, 14: 4192-4199. 10.1158/1078-0432.CCR-07-5278.
Article
CAS
PubMed
Google Scholar
Green DR, Ferguson T, Zitvogel L, Kroemer G: Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009, 9: 353-363. 10.1038/nri2545.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, Kroemer G: Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis. 2009, 14: 364-375. 10.1007/s10495-008-0303-9.
Article
PubMed
Google Scholar
Kepp O, Tesniere A, Zitvogel L, Kroemer G: The immunogenicity of tumor cell death. Curr Opin Oncol. 2009, 21: 71-76. 10.1097/CCO.0b013e32831bc375.
Article
CAS
PubMed
Google Scholar
Haynes NM, van der Most RG, Lake RA, Smyth MJ: Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol. 2008, 20: 545-557. 10.1016/j.coi.2008.05.008.
Article
CAS
PubMed
Google Scholar
Campana L, Bosurgi L, Rovere-Querini P: HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol. 2008, 20: 518-523. 10.1016/j.coi.2008.04.012.
Article
CAS
PubMed
Google Scholar
Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L, Kroemer G: Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol. 2008, 20: 504-511. 10.1016/j.coi.2008.05.007.
Article
CAS
PubMed
Google Scholar
Yang J, Shah R, Robling AG, Templeton E, Yang H, Tracey KJ, Bidwell JP: HMGB1 is a bone-active cytokine. J Cell Physiol. 2008, 214: 730-739. 10.1002/jcp.21268.
Article
CAS
PubMed
Google Scholar
Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A: HMGB1: endogenous danger signaling. Mol Med. 2008, 14: 476-484. 10.2119/2008-00034.Klune.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kusume A, Sasahira T, Luo Y, Isobe M, Nakagawa N, Tatsumoto N, Fujii K, Ohmori H, Kuniyasu H: Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology. 2009, 76: 155-162. 10.1159/000218331.
Article
CAS
PubMed
Google Scholar
Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA: Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity. 2008, 29: 21-32. 10.1016/j.immuni.2008.05.013.
Article
CAS
PubMed
PubMed Central
Google Scholar
Popovic PJ, DeMarco R, Lotze MT, Winikoff SE, Bartlett DL, Krieg AM, Guo ZS, Brown CK, Tracey KJ, Zeh HJ: High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol. 2006, 177: 8701-8707.
Article
CAS
PubMed
Google Scholar
Ulloa L, Messmer D: High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev. 2006, 17: 189-201. 10.1016/j.cytogfr.2006.01.003.
Article
CAS
PubMed
Google Scholar
Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L: Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med. 2008, 14: 141-151. 10.1016/j.molmed.2008.02.002.
Article
CAS
PubMed
Google Scholar
Hussein MR, Hassan HI: Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol. 2006, 59: 972-977. 10.1136/jcp.2005.031252.
Article
CAS
PubMed
PubMed Central
Google Scholar
Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K: Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004, 10: 8465-8471. 10.1158/1078-0432.CCR-04-0653.
Article
CAS
PubMed
Google Scholar
Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, Allavena P, Torri V, Repici A, Santoro A, Mantovani A, Roncalli M, Malesci A: CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol. 2009, 3:
Google Scholar
Wu D, Ding Y, Wang S, Zhang Q, Liu L: Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol. 2008, 216: 167-175. 10.1002/path.2391.
Article
CAS
PubMed
Google Scholar
Shen X, Hong L, Sun H, Shi M, Song Y: The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol Rep. 2009, 22: 535-539.
CAS
PubMed
Google Scholar
Cardinal J, Pan P, Dhupar R, Ross M, Nakao A, Lotze M, Billiar T, Geller D, Tsung A: Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury. Hepatology. 2009, 50: 565-574. 10.1002/hep.23021.
Article
CAS
PubMed
Google Scholar
Sharma A, Ray R, Rajeswari MR: Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest. 2008, 26: 843-851. 10.1080/07357900801954210.
Article
CAS
PubMed
Google Scholar
Jiao Y, Wang HC, Fan SJ: Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin. 2007, 28: 1957-1967. 10.1111/j.1745-7254.2007.00669.x.
Article
CAS
PubMed
Google Scholar
Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B, Bullerdiek J: Variation of HMGB1 expression in breast cancer. Anticancer Res. 2001, 21: 3881-3885.
CAS
PubMed
Google Scholar
Nagatani G, Nomoto M, Takano H, Ise T, Kato K, Imamura T, Izumi H, Makishima K, Kohno K: Transcriptional activation of the human HMG1 geneincisplatin-resistant human cancer cells. Cancer Res. 2001, 61: 1592-1597.
CAS
PubMed
Google Scholar
Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS, Ahn YH, Yoo JS, Paik YK, Kim H: Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest. 2009, 89: 948-959. 10.1038/labinvest.2009.47.
Article
CAS
PubMed
Google Scholar
Logsdon CD, Fuentes MK, Huang EH, Arumugam T: RAGE and RAGE ligands in cancer. Curr Mol Med. 2007, 7: 777-789. 10.2174/156652407783220697.
Article
CAS
PubMed
Google Scholar
Balasubramani M, Day BW, Schoen RE, Getzenberg RH: Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and high mobility group box 1 protein in the nuclear matrix associated with colon cancer. Cancer Res. 2006, 66: 763-769. 10.1158/0008-5472.CAN-05-3771.
Article
CAS
PubMed
Google Scholar
Kuniyasu H, Chihara Y, Takahashi T: Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep. 2003, 10: 445-448.
PubMed
Google Scholar
Sasahira T, Akama Y, Fujii K, Kuniyasu H: Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch. 2005, 446: 411-415. 10.1007/s00428-005-1210-x.
Article
CAS
PubMed
Google Scholar
Kuniyasu H, Chihara Y, Kondo H: Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer. 2003, 104: 722-727. 10.1002/ijc.11016.
Article
CAS
PubMed
Google Scholar
Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G: Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol. 2010, 136: 677-684. 10.1007/s00432-009-0706-1.
Article
CAS
PubMed
Google Scholar
Luo Y, Ohmori H, Fujii K, Moriwaka Y, Sasahira T, Kurihara M, Tatsumoto N, Sasaki T, Yamashita Y, Kuniyasu H: HMGB1 attenuates anti-metastatic defence of the liver in colorectal cancer. Eur J Cancer. 2010, 46: 791-799. 10.1016/j.ejca.2009.11.011.
Article
CAS
PubMed
Google Scholar
Moriwaka Y, Luo Y, Ohmori H, Fujii K, Tatsumoto N, Sasahira T, Kuniyasu H: HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology. 2010, 77: 17-23. 10.1159/000272950.
Article
CAS
PubMed
Google Scholar
Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT: Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007, 13: 2836-2848. 10.1158/1078-0432.CCR-06-1953.
Article
CAS
PubMed
Google Scholar
Chavakis E, Hain A, Vinci M, Carmona G, Bianchi ME, Vajkoczy P, Zeiher AM, Chavakis T, Dimmeler S: High-mobility group box 1activates integrin-dependent homing of endothelial progenitor cells. Circ Res. 2007, 100: 204-212. 10.1161/01.RES.0000257774.55970.f4.
Article
CAS
PubMed
Google Scholar
Schlueter C, Weber H, Meyer B, Rogalla P, Roser K, Hauke S, Bullerdiek J: Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol. 2005, 166: 1259-1263.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mitola S, Belleri M, Urbinati C, Coltrini D, Sparatore B, Pedrazzi M, Melloni E, Presta M: Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol. 2006, 176: 12-15.
Article
CAS
PubMed
Google Scholar
Sha Y, Zmijewski J, Xu Z, Abraham E: HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol. 2008, 180: 2531-2537.
Article
CAS
PubMed
Google Scholar
Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, Devera ME, Liang X, Tör M, Billiar T: The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev. 2007, 220: 60-81. 10.1111/j.1600-065X.2007.00579.x.
Article
CAS
PubMed
Google Scholar
Kuniyasu H, Sasaki T, Sasahira T, Ohmori H, Takahashi T: Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology. 2004, 71: 129-136. 10.1159/000076467.
Article
CAS
PubMed
Google Scholar
Srikrishna G, Freeze HH: Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009, 11: 615-628.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sun NK, Chao CC: The cytokine activity of HMGB1--extracellular escape of the nuclear protein. Chang Gung Med J. 2005, 28: 673-682.
PubMed
Google Scholar
Aychek T, Miller K, Sagi-Assif O, Levy-Nissenbaum O, Israeli-Amit M, Pasmanik-Chor M, Jacob-Hirsch J, Amariglio N, Rechavi G, Witz IP: E-selectin regulates gene expression in metastatic colorectal carcinoma cells and enhances HMGB1 release. Int J Cancer. 2008, 123: 1741-1750. 10.1002/ijc.23375.
Article
CAS
PubMed
Google Scholar
Kusume A, Sasahira T, Luo Y, Isobe M, Nakagawa N, Tatsumoto N, Fujii K, Ohmori H, Kuniyasu H: Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology. 2009, 76: 155-162. 10.1159/000218331.
Article
CAS
PubMed
Google Scholar
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007, 13: 1050-1059. 10.1038/nm1622.
Article
CAS
PubMed
Google Scholar
Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L: Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med. 2008, 14: 141-151. 10.1016/j.molmed.2008.02.002.
Article
CAS
PubMed
Google Scholar
Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, André F, Tursz T, Kroemer G, Zitvogel L: The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007, 220: 47-59. 10.1111/j.1600-065X.2007.00573.x.
Article
CAS
PubMed
Google Scholar
Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ: High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother. 2007, 30: 596-606. 10.1097/CJI.0b013e31804efc76.
Article
PubMed
Google Scholar
Mantell LL, Parrish WR, Ulloa L: Hmgb-1as a therapeutic target for infectious and inflammatory disorders. Shock. 2006, 25: 4-11. 10.1097/01.shk.0000188710.04777.9e.
Article
CAS
PubMed
Google Scholar
Li G, Liu W, Frenz D: Cisplatin ototoxicity to the rat inner ear: a role for HMG1 and iNOS. Neurotoxicology. 2006, 27: 22-30. 10.1016/j.neuro.2005.05.010.
Article
PubMed
Google Scholar